<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">4806</id>
  <title>T3D4751</title>
  <common-name>Dihydrotestosterone</common-name>
  <description>Dihydrotestosterone is a potent androgenic metabolite of testosterone. Dihydrotestosterone (DHT) is generated by a 5-alpha reduction of testosterone. Unlike testosterone, DHT cannot be aromatized to estradiol therefore DHT is considered a pure androgenic steroid. -- Pubchem; Dihydrotestosterone (DHT) (INN: androstanolone) is a biologically active metabolite of the hormone testosterone, formed primarily in the prostate gland, testes, hair follicles, and adrenal glands by the enzyme 5-alpha-reductase by means of reducing the alpha 4,5 double-bond. Dihydrotestosterone belongs to the class of compounds called androgens, also commonly called androgenic hormones or testoids. DHT is thought to be approximately 30 times more potent than testosterone because of increased affinity to the androgen receptor. -- Wikipedia.</description>
  <cas>521-18-6</cas>
  <pubchem-id>10635</pubchem-id>
  <chemical-formula>C19H30O2</chemical-formula>
  <weight nil="true"/>
  <appearance>White powder.</appearance>
  <melting-point>181°C</melting-point>
  <boiling-point nil="true"/>
  <density nil="true"/>
  <solubility>525 mg/mL at 25°C</solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure>Bioavailability is very low (0-2%) following oral administration.</route-of-exposure>
  <target nil="true"/>
  <mechanism-of-toxicity nil="true"/>
  <metabolism nil="true"/>
  <toxicity nil="true"/>
  <lethaldose nil="true"/>
  <carcinogenicity>No indication of carcinogenicity to humans (not listed by IARC).</carcinogenicity>
  <use-source>Dihydrotestosterone is an endogenously produced metabolite found in the human body. It is used in metabolic reactions, catabolic reactions or waste generation.</use-source>
  <min-risk-level nil="true"/>
  <health-effects nil="true"/>
  <symptoms nil="true"/>
  <treatment nil="true"/>
  <created-at type="dateTime">2014-09-11T05:14:48Z</created-at>
  <updated-at type="dateTime">2026-05-14T17:47:05Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia>http://en.wikipedia.org/wiki/Dihydrotestosterone</wikipedia>
  <uniprot-id nil="true"/>
  <kegg-compound-id>C03917</kegg-compound-id>
  <omim-id nil="true"/>
  <chebi-id>16330</chebi-id>
  <biocyc-id>17-BETA-HYDROXY-5ALPHA-ANDROSTAN-3-O</biocyc-id>
  <ctd-id nil="true"/>
  <stitch-id nil="true"/>
  <drugbank-id>DB02901</drugbank-id>
  <pdb-id>DHT</pdb-id>
  <actor-id nil="true"/>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C</moldb-smiles>
  <moldb-formula>C19H30O2</moldb-formula>
  <moldb-inchi>InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1</moldb-inchi>
  <moldb-inchikey>NVKAWKQGWWIWPM-ABEVXSGRSA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">290.4403</moldb-average-mass>
  <moldb-mono-mass type="decimal">290.224580204</moldb-mono-mass>
  <origin>Endogenous</origin>
  <state>Solid</state>
  <logp>3.55</logp>
  <hmdb-id>HMDB02961</hmdb-id>
  <chembl-id nil="true"/>
  <chemspider-id>14</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference>&lt;p&gt;A. Glenn Braswell, Aftab J. Ahmed, &amp;#8220;Composition for inhibiting production of dihydrotestosterone to treat benign prostate hyperplasia.&amp;#8221; U.S. Patent US6264996, issued October, 1996.&lt;/p&gt;</synthesis-reference>
  <structure-image-caption nil="true"/>
  <chemdb-id>CHEM003708</chemdb-id>
  <dsstox-id>DTXSID9022364</dsstox-id>
  <toxcast-id nil="true"/>
  <stoff-ident-origin nil="true"/>
  <stoff-ident-id nil="true"/>
  <susdat-id nil="true"/>
  <iupac>(1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-9a,11a-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-7-one</iupac>
  <moldb-polar-surface-area>37.3</moldb-polar-surface-area>
  <moldb-refractivity>83.60309999999998</moldb-refractivity>
  <moldb-polarizability>34.537342899421</moldb-polarizability>
  <moldb-rotatable-bond-count>0</moldb-rotatable-bond-count>
  <moldb-acceptor-count>2</moldb-acceptor-count>
  <moldb-donor-count>1</moldb-donor-count>
  <moldb-pka-strongest-acidic>19.37770535655329</moldb-pka-strongest-acidic>
  <moldb-pka-strongest-basic>-0.8839915294840951</moldb-pka-strongest-basic>
  <moldb-physiological-charge>0</moldb-physiological-charge>
  <moldb-number-of-rings>4</moldb-number-of-rings>
  <moldb-alogps-logp>3.37</moldb-alogps-logp>
  <moldb-alogps-logs>-4.46</moldb-alogps-logs>
  <moldb-alogps-solubility>9.98e-03 g/l</moldb-alogps-solubility>
</compound>
